DUBLIN--(BUSINESS WIRE)--The "Global Kaposi Sarcoma Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
Global kaposi sarcoma market was valued at US$ 108.8 Mn in 2016, and is expected to reach US$ 135.6 Mn by 2025 expanding at a CAGR of 2.44% from 2017 to 2025.
In 2016, HAART (highly active antiretroviral therapy) segment dominated the market due to rising prevalence of AIDS, as patients suffering with HIV infection are 20,000 times prone to develop Kaposi sarcoma and the proactive government initiative such as United States Presidents Emergency Plan for AIDS Relief (PEPFAR) to fight AIDS-KS. Chemotherapy will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as technological advancement in the drug formulation for e.g. paclitaxel nanosomal formulation utilized as a topical treatment for AIDS-KS surpassing the drug biotransformation which is toxic to liver cells.
Promising pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes acid sensitive linker that selectively binds to albumin to allow the cytotoxic payload to accumulate near the tumor and spare the surrounding healthy tissues.
Key Market Movements:
- Rising prevalence of AIDS-KS
- Technological advancement has led to improvement in the drug formulation such as targeted immunotherapy and nanosomes to avoid cytotoxicity to healthy cells
- Supportive regulatory environment for Kaposi sarcoma drugs
- Affordable reimbursement scenario for the treatment of Kaposi sarcoma in developed countries
Key Topics Covered:
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Kaposi Sarcoma: Market Dynamics and Future Outlook
Chapter 4. Global Kaposi Sarcoma Market, by Treatment Type, 2015 - 2025 (US$ Mn)
Chapter 5. Global Kaposi Sarcoma Market, by Geography, 2015 - 2025 (US$ Mn)
Chapter 6. Company Profiles
- Aphios Corp.
- Bristol Myers Squibb Company
- Cytori Therapeutics, Inc.
- CytRx Corporation
- Eli Lilly and Co.
- GlaxoSmithKline plc.
- F.Hoffman La-Roche, Inc.
- Johnson and Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/j8tvsb/global_kaposi?w=4